IMGN - ImmunoGen, Inc.
| Previous Close | 3.5400 |
| Open | 3.3600 |
| Bid | 3.2000 x 900 |
| Ask | 3.8000 x 1800 |
| Day's Range | 3.3400 - 3.8800 |
| 52 Week Range | 1.7600 - 7.0700 |
| Volume | 2,908,099 |
| Avg. Volume | 3,511,358 |
| Market Cap | 644.988M |
| Beta (5Y Monthly) | 2.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7020 |
| Earnings Date | Apr 30, 2020 - May 04, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.70 |
- Zacks
Why Is ImmunoGen (IMGN) Down 45.5% Since Last Earnings Report?
ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Thomson Reuters StreetEvents
Edited Transcript of IMGN earnings conference call or presentation 14-Feb-20 1:00pm GMT
Q4 2019 ImmunoGen Inc Earnings Call
- Zacks
Stock Market News for Feb 18, 2020
Benchmarks ended were mixed on Friday, as investors' attention was fixed on the rising death toll in China and the limited strength displayed by American consumers last month.
- GuruFocus.com
US Indexes Close Mostly Flat Friday With Gains for the Week
Dow Jones reports a weekly gain of 2.2% Continue reading...
- Zacks
ImmunoGen (IMGN) Q4 Earnings and Revenues Beat Estimates
ImmunoGen (IMGN) delivered earnings and revenue surprises of 160.00% and 53.43%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Will ImmunoGen (IMGN) Report Negative Earnings Next Week? What You Should Know
ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Should You Worry About ImmunoGen, Inc.'s (NASDAQ:IMGN) CEO Pay Cheque?
Mark Enyedy became the CEO of ImmunoGen, Inc. (NASDAQ:IMGN) in 2016. First, this article will compare CEO compensation...
- Benzinga
The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 22) 10X Genomics Inc (NASDAQ: TXG ) Abbott Laboratories ...
- Zacks
ImmunoGen Lead Drug Gets Nod for Accelerated Approval Pathway (Revised)
FDA approves a new pivotal study to support accelerated approval pathway for ImmunoGen's (IMGN) ovarian cancer candidate, mirvetuximab soravtansine.
- Benzinga
4 Momentum Stocks To Watch
These four stocks are moving on news and gaining technical momentum: Axsome Therapeutics, Inc . (NASDAQ: AXSM ) jumped $8.60 to $89.57 on 2.6 million shares Wednesday, more than double its average volume. ...
- Zacks
ImmunoGen (IMGN) Looks Good: Stock Adds 7.6% in Session
ImmunoGen (IMGN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
- Zacks
ImmunoGen Lead Drug Gets Nod for Accelerated Approval Pathway
FDA approves a new pivotal study to support accelerated approval pathway for ImmunoGen's (IMGN) ovarian cancer candidate, mirvetuximab soravtansine. Shares up.
- Insider Monkey
Hedge Funds Are Dumping ImmunoGen, Inc. (IMGN)
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]
- Zacks
ImmunoGen (IMGN) Up 51.7% Since Last Earnings Report: Can It Continue?
ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Roche Gets CHMP Opinion for Breast Cancer & Lymphoma Drugs
Roche's (RHHBY) breast cancer candidate and lymphona candidate get positive CHMP opinion. The company inks a deal to acquire Promedior, Inc.
- Thomson Reuters StreetEvents
Edited Transcript of IMGN earnings conference call or presentation 1-Nov-19 12:00pm GMT
Q3 2019 ImmunoGen Inc Earnings Call
- Insider Monkey
Is ImmunoGen, Inc. (IMGN) A Good Stock To Buy?
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
- Simply Wall St.
How Many ImmunoGen, Inc. (NASDAQ:IMGN) Shares Do Institutions Own?
A look at the shareholders of ImmunoGen, Inc. (NASDAQ:IMGN) can tell us which group is most powerful. Insiders often...
- Zacks
ImmunoGen (IMGN) Q3 Earnings & Sales Beat, Shares Rally
ImmunoGen (IMGN) reports narrower-than-expected third-quarter loss and beats revenue estimates. The company is set to initiate the FDA recommended phase III study on mirvetuximab soravtansine by year-end.
